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Introduction {#sec1}
============

Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition affecting reciprocal social interaction and communication, accompanied by restricted and repetitive behaviors ([@bib14]). Familial clustering of ASD and related subclinical traits has been described, and with sibling recurrence risk estimates ranging from 8.1 to 18.7 ([@bib19], [@bib36], [@bib40]), a significant amount of familial liability is attributed to genetic factors ([@bib11]). Genomic microarray and sequencing studies have identified that ∼10% of individuals have an identifiable genetic condition, and there are over 100 genetic disorders that can exhibit features of ASD, e.g., Fragile X and Rett syndromes ([@bib7]). Dozens of additional penetrant susceptibility genes have also been implicated in ASD ([@bib13], [@bib18], [@bib37], [@bib43], [@bib50]), some being used in clinical testing ([@bib10], [@bib16]). Genetically identified ASD-risk genes are enriched in broader functional groups consisting of synapse function, RNA processing, and transcriptional regulation ([@bib8], [@bib13], [@bib17], [@bib37], [@bib51], [@bib50]). Importantly, so far, each risk gene or copy number variation (CNV) implicated in ASD accounts for \<1% of cases, suggesting significant genetic heterogeneity ([@bib50]). Even within families, siblings can carry different penetrant mutations ([@bib17], [@bib28], [@bib52]). Common genetic variants may also contribute to ASD risk ([@bib45]).

Until recently, postmortem brains were the only source of human cortical neurons to study directly the mechanistic and functional roles of ASD candidate genes *in vitro* ([@bib44], [@bib47]). However, the still small numbers of biobanked brains, and the heterogeneous cellular content of the organ itself, as well as issues of cell viability and health are difficult to properly control in ASD ([@bib2], [@bib12]). The terminal differentiation status of mature neurons also precludes any potential *in vitro* studies in particular for early-onset conditions like ASD. Alternatively, somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) that can grow indefinitely *in vitro* ([@bib42]). Such patient-specific iPSCs provide a newfound ability to study developmental processes, and functional characteristics, directly. Importantly, differentiation of human iPSCs into forebrain glutamatergic neurons may lead to model systems that recapitulate early molecular events in the trajectory of ASD development ([@bib20], [@bib34]). Directed induction into excitatory neurons can be achieved with high efficiency using transient ectopic expression of the transcription factor NGN2 ([@bib53]).

We devised a precise clustered regularly interspaced short palindromic repeats (CRISPR)-based strategy to efficiently generate complete knockout (KO) of any ASD-relevant gene, with all mutations made in the same "isogenic" (identical genetic background) human control iPSC line. We used the CRISPR/Cas9-mediated double-strand break mechanism coupled with error-free single-stranded template repair (SSTR) pathways ([@bib33]) to introduce an all-reading-frame premature termination codon (named "StopTag"; [Figure 1](#fig1){ref-type="fig"}A) into a specific exon of a target gene, designed to prevent stable RNA/protein product from being made. We hypothesized that a collection of isogenic KO lines carrying different ASD-risk null mutations would best minimize the confounding effects of genetic background. We then explored excitatory neuron functional differences relevant to ASD for ten different successfully edited StopTag lines. Our results indicate that some ASD-risk genes display reduced synaptic activity between NGN2-derived excitatory neurons implying that ASD genes from different classes can present the same general cellular phenotype *in vitro.* We also highlight benefits and restrictions of studying ASD-risk genes using an isogenic human neural system.Figure 1Outline of the Experimental Procedure to Test the Phenotypical Consequences of Gene Repression in iPSC-Derived Glutamatergic Neurons(A) Unaffected human iPSC controls (ctrl) 19-2, labeled in green, were subjected to CRISPR gene editing to introduce a premature termination codon (StopTag), into a target exon of 14 ASD target genes. Knockout (KO) iPSC populations were identified by absolute quantification of StopTag versus wild-type (wt) alleles using droplet digital PCR (ddPCR). Well A1 is an example of a cell population containing 100% wt allele (FAM signal in blue) for a given target locus, while well A2 contains 100% StopTag alleles (VIC signal in green); FAM- and VIC-associated probe sequences are presented in [Table S1](#mmc1){ref-type="supplementary-material"}. KO iPSCs were differentiated into glutamatergic neurons, labeled in red, by means of NGN2 transient overexpression (O/E). Neuronal phenotypes were monitored using RNA-seq, patch-clamp, and multi-electrode array recordings; F and R are ddPCR primers.(B) Full-length integral StopTag sequence insertion was confirmed for all target genes except *CHD8*, in which the first 39 bp in 5′ of the StopTag sequence were deleted, and *ASTN2*, in which different point mutations were found (red bars); chr, chromosome; bp, base pair.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Tables S1--S3](#mmc1){ref-type="supplementary-material"}.

Results {#sec2}
=======

Selection of ASD-Risk Genes {#sec2.1}
---------------------------

We selected 14 candidate ASD susceptibility genes from our ongoing whole-genome sequencing (WGS) project (the Autism Speaks MSSNG project), which aims to generate a list of penetrant genes for clinical diagnostics ([@bib50]). The evidence and priority of each gene, at the time of its selection, for having a role in ASD is described in [Table 1](#tbl1){ref-type="table"}, as is its assignment within three different functional groupings, i.e., transcriptional regulation, RNA processing, and synaptic and adhesion. We also note the importance of considering the results from the models described below to human mutation data in ASD individuals, which can present in dominant, recessive, and X-linked recessive forms, and be influenced by the sex of the carrier ([@bib10], [@bib17]).Table 1List of 14 ASD Susceptibility Genes with Their Corresponding Functional Groupings, Transcript Levels in iPSCs, and Efficiency of TargetingGeneChrMolecular FunctionModuleASD Gene ReferenceSFARI ScoreOMIM GeneAssociated DisordersASD SyndromeRPKMTargeting Efficiency*ANKRD11*16chromatin regulationtranscriptional regulation[@bib50]2[611192](611192){#intref0020}ADHD, EPS, IDKBG syndrome26.2failed*AUTS2*7chromatin bindingtranscriptional regulation[@bib50]3--ID, DD/ND--16.6failed*ATRX*Xchromatin binding/helicasetranscriptional regulation[@bib9]4[300032](300032){#intref0025}EP, EPS--17.7Hem*CHD8*14chromatin binding/helicasetranscriptional regulation[@bib50]1[610528](610528){#intref0030}SCZ, DD/ND ID--27.8Het*AFF2* (FMR2)XRNA bindingRNA processing[@bib50]4[300806](300806){#intref0035}ID, ASD, EPS, EP, ADHDfragile X syndrome1.7Hem*CAPRIN1*11RNA bindingRNA processing[@bib23]3------110.9failed*CACNA1C*12ion channel activitysynaptic and adhesion[@bib50]S[114205](114205){#intref0040}EPS, BPD, IDTimothy syndrome0.2Hom*KCNQ2*20ion channel activitysynaptic and adhesion[@bib50]3[602235](602235){#intref0045}ADHD, DD/ND ID--7.8Hom*SCN2A*2ion channel activitysynaptic and adhesion[@bib50]1[182390](182390){#intref0050}EPS, DD/ND ADHD, ID, EP--0.3Hom*ASTN2*9calcium ion bindingsynaptic and adhesion[@bib29]3--ID, EPS, DD/ND ADHD--2.9Hom*DLGAP2*8synapsesynaptic and adhesion[@bib32]4------0.2Hom*CNTNAP2*7Cell adhesionsynaptic and adhesion[@bib4]2S[604569](604569){#intref0055}ADHD, EP, EPS, IDcortical dysplasia-focal epilepsy syndrome19.3failed*TENM1* (ODZ1)XCell adhesion/signal transducersynaptic and adhesion[@bib50]NA------0.2Hem*ANOS1* (KAL1)Xextracellular matrixsynaptic and adhesion[@bib23]NA[300836](300836){#intref0060}--Kallmann syndrome35.8Hem[^4]

StopTag Insertion into ASD-Risk Genes and the Isogenic Control iPSC Line {#sec2.2}
------------------------------------------------------------------------

We first used HEK293T cells to validate our SSTR-based strategy that involved introducing all-reading-frame premature termination codons (PTC; 3x stop; [Figure S1](#mmc1){ref-type="supplementary-material"}A) into the DNA corresponding to an early constitutive exon for each gene ([Table S1](#mmc1){ref-type="supplementary-material"}), aiming for a complete expression knockout. This insertion was delivered by a synthesized single-stranded oligodeoxynucleotide (ssODN) template ([Table S1](#mmc1){ref-type="supplementary-material"}). The inserted fragment, called "StopTag" ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A), is 59 bp in length and includes a V5 epitope coding sequence. The left homology arm of ssODN was designed to insert the V5 epitope in phase with the original reading frame in order to allow the detection of truncated protein, with potential residual activity, which might have escaped non-sense mediated decay (NMD) following PTC insertion. PCR amplification confirmed the integration of the StopTag within specific target loci in *CHD8*, *DLGAP2*, and *KCNQ2* ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

In human iPSCs, the same StopTag insertion was used to knock out each of the 14 ASD-risk genes in a pluripotent and normal iPSC line named "Ctrl 19-2" ([Figures 1](#fig1){ref-type="fig"}A and [2](#fig2){ref-type="fig"}A--2D). This line was reprogrammed from an unaffected father of a child with ASD who carries a *de novo* 16p11.2 microdeletion, associated with ASD ([@bib32], [@bib46]). WGS confirmed that the unaffected father did not carry the 16p11.2 microdeletion, or any other known ASD-risk variants. Enrichment of 19-2-derived KO iPSCs was based on droplet digital PCR (ddPCR) coupled with dilution culture steps ([Figure 1](#fig1){ref-type="fig"}A and [Table S2](#mmc1){ref-type="supplementary-material"}), adapted from [@bib33] in order to maintain the polyclonality of cellular populations during enrichment. On average, 4.2 enrichment plates per line were necessary to purify to 100% KO ([Table S2](#mmc1){ref-type="supplementary-material"}). In addition, we confirmed homozygous or hemizygous splicing of StopTag into all successful target loci ([Figures 1](#fig1){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}), except for *KCNQ2* where the second allele presented a 31-bp frameshift duplication ([Figure 1](#fig1){ref-type="fig"}B and [Table 1](#tbl1){ref-type="table"}). No overt off-target mutation was found in any KO iPSC line ([Table S3](#mmc1){ref-type="supplementary-material"}).Figure 2Characterization of the Control 19-2 iPSCs and Neurons(A--D) Representative microscopic images show normal iPSC (A) pluripotency (SSEA4 and OCT4), (B) differentiation potential into the three germ layers *in vitro* (embryoid bodies: TUBB3, SMA, and AFP) or (C) *in vivo* (teratoma assays), and (D) karyotype. See also [Figure S4](#mmc1){ref-type="supplementary-material"}. Scale bars: 100 μm (A), 25 μm (B), and 100 μm (C).(E) Representative traces of action potentials recorded at different current injection on the left panel, and the number of action potentials is plotted for each step of current injection on the right panel.(F) Representative traces of sodium currents on the left panel, and currents were recorded at different potentials in voltage-clamp on the right panel; 33 control 19-2 neurons were recorded from three independent differentiation experiments at day 21--28 post-NGN2-induction (PNI).(G) Transcript levels in RPKM of a series of iPSC, neural progenitor cell (NPC), and neuron markers in control 19-2 iPSCs (blue) and control 19-2 glutamatergic neurons (orange). Values are presented as means ± SD of eight independent experiments for iPSCs and four for neurons.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Induction into Excitatory Neurons {#sec2.3}
---------------------------------

Since genes involved in glutamatergic neurotransmission are associated with ASD ([@bib3], [@bib18]), we sought to differentiate our KO iPSC lines into excitatory neurons to explore functional differences. We used the ectopic expression of NGN2 for iPSC differentiation ([Figure 1](#fig1){ref-type="fig"}A) in order to achieve homogeneous populations of neurons, and a reproducible differentiation protocol for the simultaneous assessment of multiple cell lines affected by different mutations. Using this protocol, induced neurons, when co-cultured with glial cells, display repetitive action potentials, large inward currents, and spontaneous synaptic activity by 21 days in culture ([@bib53]). We hypothesized that NGN2-induced mutant neurons could be used to monitor ASD state *in vitro*. We therefore induced NGN2 for 7 days and assessed electrophysiological properties of 19-2 control neurons using patch-clamp recordings of 21--28 days post-NGN2-induction (PNI) in the presence of cultured mouse glial cells. These 19-2 control neurons had a similar ability to fire repetitive action potentials ([Figure 2](#fig2){ref-type="fig"}E), and comparable input resistance, inward and outward currents ([Figures 2](#fig2){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}A). Therefore, the NGN2 induction protocol was able to generate neurons to a similar maturation as previously reported ([@bib49], [@bib53]), enabling us to use the system to interrogate the function of ASD genes using isogenic KO iPSCs. Here, "neuron" refers to the NGN2-induced neuron.

Transcriptional Characterization of Control 19-2 iPSCs and Neurons {#sec2.4}
------------------------------------------------------------------

We used RNA sequencing (RNA-seq) to verify the pluripotent state of the control 19-2 iPSCs, as well as the glutamatergic state of the control 19-2 neurons 4 weeks PNI cultured in the absence of glial cells. Transcript levels of 14 well-established pluripotency markers were high, i.e., from 33 to 783 reads per kilobase of transcript per million mapped reads (RPKM) in control iPSCs ([Figure 2](#fig2){ref-type="fig"}G). Expression of the same set of pluripotency markers was low in neurons, i.e., from 0 to 14 RPKM. We observed a similar pattern of expression to that published originally in NGN2-generated neurons ([@bib53]). For example, we recorded higher levels of the cortical markers *POU3F2* and *FOXG1* than those of *TBR1* ([Figure 2](#fig2){ref-type="fig"}G). AMPA receptor subunits *GRIA1*, *GRIA2*, and *GRIA4* were highly represented at \>10 RPKM, compared with the NMDA receptor subunit *GRIN1* at 1.5 RPKM, and transcript levels for the glutamate transporter *SLC17A6* were high, while those of *SLC17A7* were much lower ([Figure 2](#fig2){ref-type="fig"}G). GABA receptor subunit *GABRA2* transcript levels were seen at higher levels compared with those of the GABA transporter *SLC32A1* ([Figure 2](#fig2){ref-type="fig"}G). We also observed high levels of the neuronal markers *MAP2*, *TUBB3*, and *NCAM1*, but near-zero levels of the astrocyte marker *GFAP* ([Figure 2](#fig2){ref-type="fig"}G). These data reflect a homogeneous NGN2-derived glutamatergic neuron profile, suitable for phenotyping.

StopTag Leads to Complete KO of Target Genes {#sec2.5}
--------------------------------------------

We ensured that the StopTag sequence was properly transcribed and fused to the different target transcripts. For example, a part of some reads generated from RNA-seq did not align with exon 2 of *SCN2A* on the human reference genome hg19 ([Figure 3](#fig3){ref-type="fig"}A), corresponding exactly to the StopTag sequence, which should cause premature termination of translation. We observed a significant reduction in transcript levels of five target genes ([Figure 3](#fig3){ref-type="fig"}B). For instance, transcript levels of *ATRX* were reduced by ∼50% in both *ATRX*^−/y^ iPSCs and neurons compared with control cells ([Figure 3](#fig3){ref-type="fig"}B). This suggests that some mutant transcripts were eliminated by NMD before complete translation due to the presence of a PTC, brought by StopTag. However, we did not observe such reduction in transcript levels for the synaptic genes *CACNA1C*, *KCNQ2*, *SCN2A*, *DLGAP2*, and *TENM1* ([Figure 3](#fig3){ref-type="fig"}B and [Table S4](#mmc1){ref-type="supplementary-material"}), suggesting that these transcripts may escape NMD at least until the time of RNA extraction. Despite transcript levels, western blot analysis confirmed the absence of target proteins in mutant neurons. For example, the major protein form of *ATRX* was detected at 280 kDa in control 19-2 neurons, but was not detectable in *ATRX*^−/y^ ([Figure 3](#fig3){ref-type="fig"}C).Figure 3Complete KO of Target Gene Expression in Neurons(A) Example of a target locus, i.e., exon 2 of *SCN2A*, where Spliced Transcripts Alignment to a Reference (STAR) software was used to align reads previously unmapped by TopHat. The gray part of the reads mapped to the human reference genome hg19. The colored part did not map to hg19 but aligned perfectly with the StopTag sequence, showing it is properly transcribed and fused to the target transcripts.(B) Transcript levels in reads per kilobase per million mapped reads (RPKM; y axis) of each target gene (x axis) in their corresponding KO iPSCs (black bars) and KO neurons (red bars), as well as in control iPSCs (gray bars) and control neurons (blue bars). Values are presented as means ± SD of 2--8 independent experiments; ^∗^FDR \<0.05 in neurons. See also [Table S4](#mmc1){ref-type="supplementary-material"}.(C) Western blots showing the absence of the major form of ATRX (upper panel) and SCN2A (bottom panel) proteins in their corresponding KO neurons, compared with control 19-2 neurons, 4 weeks PNI; ACTB, loading control.(D) Western blots revealing the absence of any truncated form of proteins in different KO neuron lines, using a V5 antibody. Predicted (kDa), predicted size of potentially truncated peptides based on the insertion sites of the StopTag within each target transcript relative to the start codon position; n/a, not applicable; ACTB and TUBB3, loading controls; n/a, not available.

Notwithstanding, some StopTag transcripts escaping NMD might still be translated as truncated proteins and not recognized by antibodies. Such peptides are undesirable in a KO setup since they can present some residual activity or cause other unintended damage ([@bib25], [@bib31]). In order to reveal the presence of any truncated form of proteins, we flanked a sequence coding for a V5 epitope upstream of the 3x stop within the StopTag fragment ([Figure 1](#fig1){ref-type="fig"}A). A perfect assemblage was confirmed by Sanger sequencing for most target genes ([Figure 1](#fig1){ref-type="fig"}B). No truncated forms of protein were detectable by western blot using a V5 antibody ([Figure 3](#fig3){ref-type="fig"}D), indicating complete absence of target proteins in the testable KO neurons.

Transcriptional Characterization of KO iPSCs and Neurons {#sec2.6}
--------------------------------------------------------

RNA-seq profiling of the ten KO iPSC lines demonstrated their pluripotency and differentiation into glutamatergic neurons. Major iPSC markers, e.g., *NANOG* and *POU5F1*, were highly expressed exclusively in iPSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}). Alternatively, specific neuronal markers, e.g., *MAP2* and *SLC17A6* (vGLUT2) were found expressed only in neurons ([Figure S3](#mmc1){ref-type="supplementary-material"}). Deficient *GFAP* expression indicated the absence of glial cells in our neuronal cultures ([Figure S3](#mmc1){ref-type="supplementary-material"}).

RNA-Seq and Pathway Analysis {#sec2.7}
----------------------------

Transcriptional co-profiling of several isogenic KO lines can reveal how different genes, belonging to different functional groupings, might regulate the expression of common gene sets or pathways. From the different lists of differentially expressed genes (DEGs) in KO iPSCs compared with controls ([Table S5](#mmc2){ref-type="supplementary-material"}), we explored common pathway enrichment shared by at least three of the ten KO lines. Several different gene ontology terms and pathways associated with "neuron projection development" presented a similar profile in different KO iPSC lines ([Figure 4](#fig4){ref-type="fig"}A). For example, most of the corresponding gene sets were downregulated in *ATRX*-, *ASTN2*-, and *DLGAP2*-, while they were upregulated in *AFF2*-null iPSCs ([Figure 4](#fig4){ref-type="fig"}A). A different profile was observed with the "anchored component of membrane" pathway, i.e., predominantly upregulated in *AFF2*- and *SCN2A*-, while downregulated in *ATRX*- and *ASTN2*-null lines ([Figure 4](#fig4){ref-type="fig"}A). Another group of gene sets, associated with "negative regulation of transcription" were commonly downregulated in *ATRX*-, and upregulated in *AFF2*- and *SCN2A*-null iPSCs ([Figure 4](#fig4){ref-type="fig"}A). In general, KO of *CACNA1C* or *KCNQ2* did not have significant impact on transcriptional networks in iPSCs ([Figure 4](#fig4){ref-type="fig"}A). This may suggest that some of our KO iPSC lines already show transcriptional networks that are prone to ASD-related changes.Figure 4Transcriptional Characterization of KO iPSCs and Neurons(A) Enrichment map of differentially expressed genes in different mutant iPSCs compared with the isogenic control 19-2, as revealed by RNA-seq and pathway analysis. For example, the upper right piece of each pie represents the *SCN2A*-null iPSC line (see inset), in which different gene sets associated with "embryonic morphogenesis" are upregulated (red color), with respect to the control 19-2 line. The color intensity correlates with the Benjamini-Hochberg false discovery rate (BH-FDR) values, as depicted in the inset. Values were calculated from (n) independent experiments; n = 8 for ctrl 19-2; n = 4 for *ATRX*^−/y^, *KCNQ2*^−/−^, *SCN2A*^−/−,^ and *ASTN2*^−/−^; n = 2 for *AFF2*^*−*/y^.(B) Differentially expressed genes in different KO neurons compared with the isogenic control 19-2 as revealed by RNA-seq. Values are presented as log2 fold change. Values were calculated from (n) independent differentiation experiments; n = 5 for *AFF2*^*−/y*^; n = 4 for ctrl 19-2, *ATRX*^*−/y*^, *KCNQ2*^−/−^, *SCN2A*^−/*−*^; n = 3 for *ASTN2*^*−/−*^.(C) RNA-seq validation of transcript levels of seven genes in three different *AFF2*-null neuron lines, i.e., 19-2-*AFF2*^*−/y*^-1, 19-2-*AFF2*^*−/y*^-2, and 50B-*AFF2*^*−/y*^, compared with their respective control lines 19-2 and 50B. Values are presented as means ± SD of (n) independent differentiation experiments where n = 4 for controls 19-2 and 50B; n = 5 for 19-2-AFF2^−/y^-1; n = 3 for 19-2-AFF2^−/y^-2 and 50B-AFF2^−/y^; ^∗^each KO line value has an FDR \<0.5 compared with its respective control line.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Tables S5--S7](#mmc2){ref-type="supplementary-material"}.

We also mined RNA-seq data for common mechanisms in our iPSC-derived NGN2 neurons. Since the number of DEGs passing a false discovery rate (FDR) \<0.05 was substantially lower in neurons overall compared with iPSCs, we decided to lower the significance thresholds for some of the KO lines and searched for pathway enrichments, as explained in [Table S6](#mmc3){ref-type="supplementary-material"}. Gene ontology terms with a Benjamini-Hochberg false discovery rate (BH-FDR) \<0.05, and associated with "neurons" or "synapses," were found in high numbers only in *ATRX*^*−/y*^ and *TENM1*^*−/y*^ lines ([Table S6](#mmc3){ref-type="supplementary-material"}). Therefore, we searched for common DEGs, instead of gene sets, found in at least two of ten mutant neuron lines. Several DEGs were shared between distinct KO neuron lines. For instance, *ZNF558* was downregulated in *ATRX-*, *AFF2-*, *KCNQ2-*, *SCN2A-*, *ASTN2-*, and *DLGAP2*-null neurons ([Figure 4](#fig4){ref-type="fig"}B). Conversely, *REG1A* was upregulated in *ATRX*-, *AFF2*-, and *TENM1*-null neurons ([Figure 4](#fig4){ref-type="fig"}B). Like in iPSCs, KO of *CACNA1C* did not have a major impact on the neuronal transcriptional network ([Figure 4](#fig4){ref-type="fig"}B). Interestingly, many upregulated DEGs shown in [Figure 4](#fig4){ref-type="fig"}B are also members of the cadherin superfamily PCDH involved in synapse configuration ([@bib21]). Inversely, several downregulated DEGs belong to the C~2~H~2~ zinc finger superfamily ZNF of putative transcription factors ([@bib30]) ([Figure 4](#fig4){ref-type="fig"}B).

On a per line basis, we searched for enrichment in ASD-associated genes among the DEGs from each KO neuron line. For this, we used a proprietary list of 736 genes (highlighted in blue in [Table S7](#mmc4){ref-type="supplementary-material"}) associated with ASD ([@bib1], [@bib37], [@bib50]). The DEGs overlapping this list are highlighted in yellow for each of our KO neuron lines in [Table S7](#mmc4){ref-type="supplementary-material"}. The number of ASD-associated genes that are differentially expressed is clearly higher in *ATRX*^*−/y*^ or in *TENM1*^*−/y*^ neurons (n \> 30) compared with each of the other KO lines (n \< 5; [Table S7](#mmc4){ref-type="supplementary-material"}), in agreement with the number of "neuron"-associated terms in the pathway enrichment analysis ([Table S6](#mmc3){ref-type="supplementary-material"}). Interestingly, among the ASD-associated genes in yellow, some are concomitantly differentially expressed in separate KO lines, e.g., *GPR139* and *HTR3A*, in *ATRX*^−/y^, *KCNQ2*^−/−^, and *ASTN2*^−/−^ neurons ([Table S7](#mmc4){ref-type="supplementary-material"}). The differential expression analyses in both iPSCs and neurons suggest common pathways and DEGs that converge toward different synaptic factors potentially affecting functional activity of neurons ([Figures 4](#fig4){ref-type="fig"}A and 4B).

RNA-Seq Validation in a Different Genetic Background {#sec2.8}
----------------------------------------------------

We also suppressed the expression of *AFF2* in a different and unrelated iPSC line, namely 50B, which presented a normal pluripotency and karyotype ([Figure S4](#mmc1){ref-type="supplementary-material"}). In addition to this new KO line, i.e., 50B-*AFF2*^*−/y*^, we generated a second KO line in the 19-2 background using the same method as the first 19-2-*AFF2*^*−/y*^ line. For optimal homogeneity of neuronal cultures, we used the same NGN2 induction protocol to obtain iPSC-derived glutamatergic neurons, on which we performed RNA-seq and differential expression analysis. We searched for significant DEGs in common with all these three *AFF2*-null lines, i.e., 19-2-*AFF2*^*−/y*^-1, 19-2-*AFF2*^*−/y*^-2, and 50B-*AFF2*^*−/y*^, compared with their respective control lines 19-2 and 50B. At least seven DEGs met these criteria, i.e., *AFF2*, *COMT*, *PPIEL*, *TXNRD2*, *ZNF558*, *ZNF736*, and *LOC728024* ([Figure 4](#fig4){ref-type="fig"}C). These results confirm that at least these genes show transcript levels that are influenced by *AFF2*, and not only by the specific 19-2 genetic background. Accordingly, we found a low total number of DEGs in both genetic backgrounds ([Figure S4](#mmc1){ref-type="supplementary-material"}C), which is in line with the absence of evidence for a transcriptional role of *AFF2* in the literature.

Patch-Clamp Electrophysiological Analysis of KO Neurons {#sec2.9}
-------------------------------------------------------

To determine if neuronal behavior was affected by any specific gene KO, we performed patch-clamp recordings on all isogenic KO neuron lines 21--28 days PNI, in co-culture with astrocytes to improve maturation. As shown in [Figure S5](#mmc1){ref-type="supplementary-material"}A, overall we did not detect consistent changes in baseline properties in neurons, indicating a similar level of maturity for all KO neurons compared with controls and that individual alterations were not specific to a particular gene. *SCN2A*-deficient neurons were a notable exception since they were significantly altered in all parameters ([Figure S5](#mmc1){ref-type="supplementary-material"}A), which is consistent with the known role of sodium currents in regulating neuronal excitability in mouse postnatal neurons ([@bib38]).

We also measured neuronal activity using patch-clamp electrophysiology as this is perhaps more relevant to ASD. We found that overall, there was a significant reduction in neuronal activity based on the observation of significantly reduced spontaneous excitatory postsynaptic current (sEPSC) frequency in *ATRX*-, *AFF2*-, *KCNQ2*-, *SCN2A*-, and *ASTN2*-null neurons, without a corresponding change in amplitude ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, *CACNA1C*^−/−^, *DLGAP2*^−/−^, and *ANOS1*^*−*/y^ neurons also displayed non-significant reductions in sEPSC frequency ([Figure 5](#fig5){ref-type="fig"}A). Conversely, *TENM1*^*−*/y^ tended toward a non-significant higher frequency of sEPSC compared with the isogenic control neurons ([Figure 5](#fig5){ref-type="fig"}A). Together, these data indicate that ASD-risk genes from different classifications can produce a similar electrophysiological phenotype.Figure 5Electrophysiological Phenotyping of KO iPSC-Derived Neurons(A) Representative traces of excitatory postsynaptic current (EPSC; top panel); spontaneous EPSC frequency (lower left panel) and amplitude (lower right panel) were recorded from different KO neurons; total number of recorded neurons is indicated on the graphs; values are presented as means ± SEM of three independent differentiation experiments for all, except two for *AFF2* and *KCNQ2*, recorded at day 21--28 PNI.(B) Representative raster plots over a 5-min recording of multi-electrode array experiments (top panels); mean firing rate (lower left panel), burst frequency (lower middle panel), and network burst frequency (lower right panel) were recorded for the five significant genes from the sEPSC frequency graph in (A). Each spike is represented with a short black line. A burst was considered as a group of at least five spikes, each separated by an inter-spike interval (ISI) of no more than 100 ms. A network burst (pink lines) was identified as a minimum of ten spikes with a maximum ISI of 100 ms, occurring on at least 25% of electrodes per well. From 21 to 55 different wells were recorded per line, with usually 6--8 wells per line per experiment. Values are presented as means ± SEM from (n) independent differentiation experiments, where n = 8 for ctrl 19-2; n = 6 for *ATRX*^−/y^; n = 5 for *SCN2A*^−/−^; n = 4 for *AFF2*^*−*/y^, *ASTN2*^−/−^, and *KCNQ2*^−/−^; recorded at week 8 PNI; ^∗^p \< 0.05 from one-way ANOVA (Dunnett multiple comparison test). n/d, not detected.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Multi-electrode Array Analysis of KO Neurons {#sec2.10}
--------------------------------------------

The increased density of neuronal processes \>28 days PNI prevented consistent clean patch-clamp recordings for longer time periods. Nonetheless, a multi-electrode array (MEA) device allows for the ability to monitor the excitability of a population of neurons in an unbiased manner by incorporating the activity of all of individual neurons in a whole well, and for long time periods in the same culture plate. We monitored the spontaneous neuronal network activity 4--8 weeks PNI using MEAs in 48-well format, in co-culture with astrocytes to improve maturation. Field recordings were acquired to estimate the activity in each well. We focused on the five genes that significantly reduced neuronal activity in [Figure 5](#fig5){ref-type="fig"}A, i.e., *ATRX*, *AFF2*, *KCNQ2*, *SCN2A*, and *ASTN2*. We sought to determine if any of these KOs would interfere with synchronized bursting events on a neuronal population level. Since the highest level of mean firing rate (MFR) was observed 8 weeks PNI in control 19-2 neurons ([Figure S5](#mmc1){ref-type="supplementary-material"}B), we opted to use this time point for comparison of all KO lines. We also confirmed that most of the cultures were composed of glutamatergic neurons using different receptor inhibitors ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

The MFR and network burst frequency were significantly reduced in *SCN2A*-null neurons compared with control ([Figure 5](#fig5){ref-type="fig"}B). Moreover, the burst frequency was lower in *ATRX-, AFF2-*, *KCNQ2-*, and *SCN2A-*null neurons ([Figure 5](#fig5){ref-type="fig"}B), suggesting that loss of function of these genes affects extracellular spontaneous network activity in glutamatergic neurons and reduces neuronal activity on a population level over a longer period of time. The absence of *AFF2* in a different genetic background, i.e., 50B-*AFF2*^*−*/y^, also led to electrophysiological deficits ([Figure S5](#mmc1){ref-type="supplementary-material"}D), confirming its role in neuronal activity. Importantly, these data are overall consistent on a per gene level compared with the sEPSC data obtained from individual neurons in [Figure 5](#fig5){ref-type="fig"}A, except *ASTN2*, and suggest that ASD-risk genes converge to disrupt excitatory neuronal activity.

Discussion {#sec3}
==========

We developed a new CRISPR-based strategy, named StopTag insertion, to completely and specifically knock out the expression of ASD-relevant genes. This approach allows the systematic generation of multiple isogenic KO lines and pairs well with the highly consistent NGN2 induction to study excitatory neurons. This combination is suitable for deep phenotyping of several isogenic human glutamatergic neuron cultures, which were shown to be relevant to ASD in several studies ([@bib20], [@bib34]). The approach revealed that a common phenotype between some "functionally" diverse ASD-risk genes is reduced synaptic activity. We demonstrated that electrophysiological properties of *ATRX*-, *AFF2*-, *KCNQ2*-, *SCN2A*-, and *ASTN2*-mutant neurons were severely compromised using two complementary electrophysiology approaches, i.e., patch-clamp and MEA, which allowed for more convincing conclusions when combined together. We also showed that ASD genes from different classes display disruption of common signaling networks that are associated with neuron projection and synapse assembly. These results indicate that aberrant functional connectivity is a frequent phenotype in human neurons with ASD candidate gene null mutations.

We obtained a high rate of biallelic editing, i.e., four of the six successful autosomal genes *CHD8*, *CACNA1C*, *KCNQ2*, *SCN2A*, *ASTN2*, and *DLGAP2*. This is possibly due to the use of plasmids to express Cas9 and gRNAs, which are expected to be stable for a few days following nucleofection. We reasoned that the impact of a full KO on transcriptional networks might be more significantly detected compared with heterozygous cells, especially for ASD-relevant genes that act under a dominant model, and/or other genes exquisitely sensitive to dosage alterations. It will be worthwhile to attempt to make heterozygous mutants when possible, using different vectors such as the RNP complex, to compare the heterozygous state of ASD variants. However, many of the ASD-risk genes are located on chromosome X, and since 19-2 cells are of male origin, these genes were fully inactivated after one allele was targeted. A notable exception was *CHD8*, which was heterozygous. Despite an attempt to target our *CHD8*^*+/−*^ line in a second round of CRISPR experiments, we failed to isolate any biallelic *CHD8*-null line. It is possible that at least one copy of *CHD8* is indispensable for survival, as proposed previously by other teams regarding mice ([@bib35]) and humans ([@bib6]). Since no significant results were obtained in this study with *CHD8*^+/−^ cells, some specific phenotypes might be more difficult to replicate with heterozygous loss-of-function mutations, possibly due to lower penetrance.

The NGN2-neuron system may represent an advantage compared with classic dual-SMAD inhibition differentiation protocols for phenotyping experiments that require relatively high levels of cell homogeneity. Dual-SMAD inhibition neurons are more heterogeneous, including several different types of cells, they require a longer time to mature, and may not be ideal for higher-throughput studies where multiple genes need to be compared. We found that scalability and consistency are improved by the NGN2 induction protocol. Moreover, it allows the neuronal phenotype to be tested directly and eliminates any contribution from mutant glial cells. However, one caveat to the NGN2 approach is the lack of inhibitory neurons, which may be important to analyze particular ASD genes expressed in this population, e.g., *ARID1B* ([@bib24]). In addition, our data suggest that a disruption in the excitation/inhibition balance contributes to ASD ([@bib22], [@bib41]). However, to test this directly, the effect on inhibitory neurons will have to be evaluated in the future ([@bib48]).

Interestingly, the five genes with a common sEPSC reduced neuronal activity phenotype ([Figure 5](#fig5){ref-type="fig"}A) fall into different molecular function groupings, i.e., *ATRX* in transcriptional regulation, *AFF2/FMR2* in RNA processing, and *KCNQ2, SCN2A, ASTN2* in synaptic and adhesion ([Table 1](#tbl1){ref-type="table"}). And KO of three of them, i.e., *ATRX*, *AFF2*, *SCN2A* (from three different groupings), converge to common transcriptional networks associated with, for example, "transcription regulation," "membrane components," and "embryonic morphogenesis" in iPSCs ([Figure 4](#fig4){ref-type="fig"}A), suggesting that early developmental events may be involved in the ASD trajectory. We also found common DEGs among the five sEPSC-featured mutant neurons, e.g., *PCDHA6*, *REG1A*, and *ZNF558* ([Figure 4](#fig4){ref-type="fig"}B), that might be responsible for this common phenotype. These results suggest that RNA-seq could be used to detect specific transcriptional signatures associated with ASD. Several DEGs were also shared between neurons mutant for genes from the same group, e.g., *KCNQ2* and *SCN2A*, which are both ion channel subunits; and between neurons mutant for *ATRX* and *AFF2*, which are both X-linked genes involved in intellectual disability and binding G4-quadruplexes associated with DNA and RNA, respectively ([@bib5], [@bib26]) ([Figure 4](#fig4){ref-type="fig"}B). Although the total number of DEGs was relatively low in our KO neurons, some were validated in a different genetic background (line 50B in [Figure 4](#fig4){ref-type="fig"}C) and were previously associated with ASD, including *COMT*, which was associated with schizophrenia ([@bib27]). Different reasons to account for the low number of DEGs found overall in neurons can be posited. For instance, despite relative cell homogeneity obtained with the NGN2 induction system, we believe that our neuron cultures presented higher levels of variation in cell composition compared with our iPSC cultures, and that such variation decreased the statistical power to find DEGs. Another reason may be that the impact on transcriptional networks occurs prior to terminal differentiation of NGN2 neurons, e.g., on proliferation of neural progenitor cells (NPCs) as previously shown with *Chd8* in mice ([@bib15]).

In conclusion, we have designed a CRISPR gene editing strategy for complete KO of ten ASD-risk genes of varying function and shown that they can be responsible for similar transcriptional rewiring and electrophysiological phenotypes in human iPSC-derived glutamatergic neurons. Overall, given the heterogeneity involved in ASD ([@bib52], [@bib50]), we believe that this type of CRISPR-isogenic KO system may be essential for stepwise controlled cellular phenotyping experiments. Whole-animal murine KO models would also be useful but the same efficiencies would not be possible. For future experiments, our isogenic KO system could also be used for the incremental creation of isogenic knockin lines where other ASD patient mutations, combinatorically, could be introduced, creating a resource for advanced functional modeling and new therapeutic testing.

Experimental Procedures {#sec4}
=======================

Reprogramming of iPSCs was performed under the approval of the Canadian Institutes of Health Research Stem Cell Oversight Committee, and the Research Ethics Board of The Hospital for Sick Children, Toronto. Reprogramming was performed from skin fibroblasts or blood cells using retrovirus, lentivirus, or Sendai virus to deliver the reprogramming factors, and iPSCs were maintained in mTeSR (STEMCELL Technologies); see [Supplemental Information](#app3){ref-type="sec"}. The type II CRISPR/Cas9 double-nicking (Cas9D10A) ([@bib39]) system with dual guide RNA ([Table S1](#mmc1){ref-type="supplementary-material"}), or ribonucleoprotein (RNP complexes) was used to insert the StopTag fragment in the presence of an ssODN template, and off-target events were searched using WGS (details in the [Supplemental Information](#app3){ref-type="sec"}). Isolation of edited iPSCs was based on ddPCR and enrichment steps and was adapted from [@bib33] (see [Supplemental Information](#app3){ref-type="sec"}). Induction of iPSCs into glutamatergic neurons was conducted using overexpression of NGN2 for a week as described in [Supplemental Information](#app3){ref-type="sec"}. For RNA-seq, RNA libraries were prepared using NEBNext Ultra RNA Library Preparation kit for Illumina, and total RNA was used for poly(A) mRNA enrichment; pathway enrichment analysis was performed using the R package goseq version 1.28.0 and R version 3.4.1 (June 30, 2017) using a custom gene-set collection including gene ontology (GO, obtained from the R package GO.db version 3.4.1) and pathways (KEGG and Reactome collections downloaded from the respective websites on October 16, 2017); see [Supplemental Information](#app3){ref-type="sec"} for more details. In electrophysiology, whole-cell recordings (BX51WI; Olympus) were performed at room temperature using an Axoclamp 700B amplifier (Molecular Devices) from borosilicate patch electrodes (P-97 puller; Sutter Instruments); multi-electrode array recordings were made using the Axion Maestro MEA reader (Axion Biosystems), as described in the [Supplemental Information](#app3){ref-type="sec"}.

Author Contributions {#sec5}
====================

E.D., R.K.C.Y., K.K.S., J.E., and S.W.S. designed the research project. E.D., S.H.W., M.F., P.J.R., W.W., and A.P. contributed to cell maintenance, characterization, and differentiation. E.D. conceived the StopTag KO strategy. E.D., M.F., and K.Z. contributed to the CRISPR experiments. Z.W. performed WGS off-target analyses. D.C.R. performed western blots. R.A., G.P., B.T., E.D., G.K., and D.M. participated in RNA-seq and pathway analysis. E.D. and S.H.W. performed electrophysiological experiments. J.L.H., V.K., S.W., A.C.L., and P.P. provided technical help. E.D., S.H.W., K.K.S., J.E., and S.W.S. wrote the manuscript and supervised the project. Specific contributions of the co-corresponding authors: K.K.S. lab differentiated iPSCs to neurons and conducted patch-clamp electrophysiology experiments; J.E. lab generated iPSC and differentiated to neurons for expression analyses and multi-electrode arrays; S.W.S. lab performed the CRISPR editing, WGS, and RNA-seq experiments.

Accession Numbers {#app1}
=================

The accession number for the RNA-seq and WGS data reported in this paper is GEO: [GSE107878](ncbi-geo:GSE107878){#intref0010}. Specific iPSC lines are available upon request.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S5, and Tables S1--S4Table S5. Lists of Statistically Significant Differentially Expressed Gene Symbols in the Different Knockout iPSC Lines, Related to Figure 4Table S6. Lists of Enrichment Terms in Different KO Neuronal Lines (Different Threshold Values Were Used to Select DEGs as Explained in Parentheses Besides the Line IDs), Related to Figure 4Table S7. Lists of Differentially Expressed Gene Symbols in the Different Knockout Neuron Lines, According to the Significance Thresholds Described in Table S6, Related to Figure 4Document S2. Article plus Supplemental Information

We thank the Autism Speaks MSSNG project for genomic data and linking to research ethics board-approved consented families. We also thank Drs. Melissa Carter, Wendy Roberts, Brian Chung, and Rosanna Weksberg for obtaining skin biopsies and blood work, and the families for volunteering. We also thank Sergio Pereira, Wilson Sung, Thomas Nalpathamkalam, Darwin D\'Souza, Joe Whitney, Jeff MacDonald, and Liz Li for bioinformatic support; Tara Paton, Guillermo Casallo, Barbara Kellam, Ny Hoang, and Sylvia Lamoureux for technical help; T.C. Südhof for the NGN2/rtTA lentiviral constructs. Supported by the Centre for Applied Genomics, Canada, the Canadian Institutes of Health Research (CIHR), Canada, the Canadian Institute for Advanced Research (CIFAR), Canada, the McLaughlin Centre, Canada, the Canada Foundation for Innovation (CFI), Canada, the Ontario Research Fund (ORF), Autism Speaks, United States, and the Hospital for Sick Children, Canada, Foundation. Scholarships and funding was from CIHR (FDN 143295 and XGG-125818) and ORF (GL2-01-013) to S.W.S., CFI-John R. Evans Leaders Fund (JELF)/ORF and CIHR (EPS-129129) to J.E.; CIHR (148814), Ontario Brain Institute (OBI), Canada, Natural Sciences and Engineering Research Council (NSERC), Canada, and the Scottish Rite Charitable Foundation to K.K.S.; NIH (4R33MH087908), United States, to J.E. and S.W.S.; Province of Ontario Neurodevelopmental Disorders (POND) from OBI to J.E., S.W.S., and K.K.S.; E.D. was a recipient of the Banting Post-Doctoral Fellowship and the Fonds de Recherche en Santé du Québec (FRQS) Post-Doctoral Fellowship; S.H.W. was supported by a Fellowship from the Fragile X Research Foundation of Canada; D.C.R. received the International Rett Syndrome Foundation, United States, Fellowship; P.J.R. was supported by the Ontario Stem Cell Initiative Fellowship and the Ontario Ministry of Research & Innovation Fellowship; K.Z. was a recipient of the CIHR Canada Vanier Graduate Scholarship. S.W.S. holds the GlaxoSmithKline-CIHR chair in Genome Sciences at the University of Toronto and the Hospital for Sick Children.

Supplemental Information includes Supplemental Experimental Procedures, five figures, and seven tables and can be found with this article online at [https://doi.org/10.1016/j.stemcr.2018.10.003](10.1016/j.stemcr.2018.10.003){#intref0015}.

[^1]: Present address: Department of Biology, University of Prince Edward Island, Charlottetown, PE C1A 4P3, Canada

[^2]: Present address: Deep Genomics Inc., Toronto, ON M5G 1M1, Canada

[^3]: Co-senior author

[^4]: Some genes like *ANOS1* and *TENM1* were considered stronger candidates for having a role in ASD early in the study, but this changed as additional genetic studies were published. SFARI, Simons Foundation Autism Research Initiative; OMIM, Online Mendelian Inheritance in Man; ADHD, attention deficit with hyperactivity disorder; EPS, extrapyramidal symptoms; ID, intellectual disability; ASD, autism spectrum disorder; EP, epilepsy; SCZ, schizophrenia; DD/NDD, developmental delay/neurodevelopmental disorder; BPD, bipolar disorder; RPKM, reads per kilobase per million mapped reads in iPSCs; Hem, hemizygous; Het, heterozygous; Hom, homozygous; NA, not available. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.
